XenoPort, Inc. - We are a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. In April 2011, the FDA approved our first product, Horizant™ (gabapentin enacarbil) Extended-Release Tablets. Our collaborator, GlaxoSmithKline (GSK), is currently promoting Horizant in the United States. We are also developing gabapentin enacarbil with Astellas Pharma Inc. in Japan and five Asian countries. XenoPort’s product candidates are being developed for the potential treatment of neuropathic pain, spasticity and Parkinson’s disease.

For more information, please click here

Wed, 02 May 2012 XenoPort Reports First Quarter Financial Results Tue, 01 May 2012 XenoPort to Present at the Deutsche Bank Annual Health Care Conference   Q1 2012 XenoPort, Inc. Earnings Conference Call Wednesday, May 2, 2012 5:00 p.m. ET  XenoPort, Inc at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference Tluesday, May 8, 2012 11:20 a.m. ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including neuropathic pain, spasticity and Parkinson’s disease. Explore the XenoPort Pipeline >